These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24492687)

  • 21. Serum bisphenol A and progression of type 2 diabetic nephropathy: a 6-year prospective study.
    Hu J; Yang S; Wang Y; Goswami R; Peng C; Gao R; Zhou H; Zhang Y; Cheng Q; Zhen Q; Li Q
    Acta Diabetol; 2015 Dec; 52(6):1135-41. PubMed ID: 26321107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.
    Yabe D; Seino Y
    Expert Opin Drug Saf; 2016; 15(2):249-64. PubMed ID: 26607297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset.
    Min T; Davies GI; Rice S; Chess J; Stephens JW
    Diabetes Metab Syndr; 2018; 12(2):123-127. PubMed ID: 29239764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin.
    Naik H; Czerniak R; Vakilynejad M
    Br J Clin Pharmacol; 2016 Apr; 81(4):700-12. PubMed ID: 26617339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
    DeFronzo RA; Fleck PR; Wilson CA; Mekki Q;
    Diabetes Care; 2008 Dec; 31(12):2315-7. PubMed ID: 18809631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B-type natriuretic peptide and renal function in Japanese patients with type 2 diabetes mellitus: The Dogo Study.
    Furukawa S; Sakai T; Niiya T; Miyaoka H; Miyake T; Yamamoto S; Tanaka K; Ueda T; Senba H; Torisu M; Minami H; Matsuura B; Hiasa Y; Miyake Y
    Endocr J; 2017 Dec; 64(12):1131-1136. PubMed ID: 28855437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients.
    Negro R; Greco EL; Greco G
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):215-219. PubMed ID: 29558784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
    Asakawa T; Moritoh Y; Kataoka O; Suzuki N; Takeuchi K; Odaka H
    Life Sci; 2009 Jul; 85(3-4):122-6. PubMed ID: 19427871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of various equations for estimating renal function in elderly Chinese patients with type 2 diabetes mellitus.
    Guo M; Niu JY; Ye XW; Han XJ; Zha Y; Hong Y; Fang H; Gu Y
    Clin Interv Aging; 2017; 12():1661-1672. PubMed ID: 29070944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between decreasing estimated glomerular filtration rate and risk of cardiac conduction defects in patients with type 2 diabetes.
    Mantovani A; Rigolon R; Turino T; Pichiri I; Falceri A; Rossi A; Temporelli PL; Bonapace S; Lippi G; Zoppini G; Bonora E; Byrne CD; Targher G
    Diabetes Metab; 2018 Dec; 44(6):473-481. PubMed ID: 30195089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
    Barnett AH; Mithal A; Manassie J; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Lancet Diabetes Endocrinol; 2014 May; 2(5):369-84. PubMed ID: 24795251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus.
    Go AS; Yang J; Tan TC; Cabrera CS; Stefansson BV; Greasley PJ; Ordonez JD;
    BMC Nephrol; 2018 Jun; 19(1):146. PubMed ID: 29929484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alogliptin (nesina) for type 2 diabetes.
    Med Lett Drugs Ther; 2013 May; 55(1417):41-3. PubMed ID: 23715128
    [No Abstract]   [Full Text] [Related]  

  • 35. Alogliptin benzoate for the treatment of type 2 diabetes.
    Rendell M; Drincic A; Andukuri R
    Expert Opin Pharmacother; 2012 Mar; 13(4):553-63. PubMed ID: 22296609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study.
    Kanaoka T; Tamura K; Moriya T; Tanaka K; Konno Y; Kondoh S; Toyoda M; Umezono T; Fujikawa T; Ohsawa M; Dejima T; Maeda A; Wakui H; Haku S; Yanagi M; Mitsuhashi H; Ozawa M; Okano Y; Ogawa N; Yamakawa T; Mizushima S; Suzuki D; Umemura S
    Clin Exp Hypertens; 2011; 33(4):255-63. PubMed ID: 21699452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of alogliptin on fractional flow reserve evaluated by coronary computed tomography angiography in patients with type 2 diabetes: Rationale and design of the TRACT study.
    Nozue T; Fukui K; Takamura T; Sozu T; Hibi K; Kishi S; Michishita I
    J Cardiol; 2017 Mar; 69(3):518-522. PubMed ID: 27236239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of sex and glucose-lowering treatments on hypoglycaemic symptoms in people with type 2 diabetes and chronic kidney disease. The French Chronic Kidney Disease - Renal Epidemiology and Information Network (CKD-REIN) Study.
    Balkau B; Metzger M; Andreelli F; Frimat L; Speyer E; Combe C; Laville M; Jacquelinet C; Briançon S; Ayav C; Massy Z; Pisoni RL; Stengel B; Fouque D
    Diabetes Metab; 2019 Apr; 45(2):175-183. PubMed ID: 29706470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Body mass index has no effect on rate of progression of chronic kidney disease in subjects with type 2 diabetes mellitus.
    Mohsen A; Brown R; Hoefield R; Kalra PA; O'Donoghue D; Middleton R; New D
    J Nephrol; 2012; 25(3):384-93. PubMed ID: 22241634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.